Ann-Tove Kongsnes

EXACT Therapeutics ("EXACT-Tx") is a clinical-stage biopharmaceutical company developing a technology platform for targeted therapeutic enhancement – Acoustic Cluster Therapy (ACT®). ACT® is a unique approach to ultrasound-mediated, targeted drug enhancement – with the potential to significantly amplify the clinical utility of a wide range of therapeutic agents across a multitude of indications including within oncology (chemotherapy, immunotherapy), infectious diseases, and neurological conditions.

Mitral Regurgitation is the third most common cardiovascular disease that occurs when there is backward flow of blood across the mitral valve. It is highly prevalent, debilitating for patients, and deadly if untreated. The market is expected to be larger than the TAVR market, currently a $6B market. The CardioMech device is an artificial chord that is designed to reduce or eliminate regurgitation and to restore the native anatomy. This catheter-based therapy is intended to be a simple and straightforward procedure and an alternative therapy option for both patients eligible for open-heart surgery and those considered surgically ineligible. Therefore, the CardioMech device can potentially reduce the need for open-heart surgery and may lessen the need for watchful waiting in younger and healthier patients. Caution: Investigational device. Limited by law to investigational use.

Curida is a Contract Development and Manufacturing Organization for Pharmaceuticals, based in Norway. We are building on more than 40 years of experience and offer premium quality manufacturing to international pharma companies. Curida has core competency on sterile and aseptic manufacturing of liquid pharmaceuticals. Our core technologies are blow-fill-seal (BFS) and nasal spray. We work with companies ranging from small biotech to Big Pharma. We have a lean and flexible organization that will, enabling a strong partnership with our customers.

SpinChip Diagnostics is a medical device company that is developing a game changing and proprietary platform for in vitro diagnostics point of care analyses. The platform will make it possible to perform a broader range of analyses using one platform and to transfer analyses from central laboratories to point of care without loss in quality. All analyses are performed within a few minutes based on a fraction of a droplet of blood and at a unit cost significantly lower than other point of care platforms.

Numascale is the eco-system enabler for scale-up in the computer industry. Numascale provides state of the art Node Controller IP, technology and components for Intel UPI and AMD Hypertransport. Numascale is also developing IP and products for CXL. www.numascale.com

Calliditas is a specialty pharmaceutical company developing high value products for patients with significant unmet medical needs. With a highly experienced, dynamic management team, Calliditas draws on its extensive experience of pharmaceutical development and marketing to efficiently identify and progress valuable and de-risked products.

EXACT Therapeutics ("EXACT-Tx") is a clinical-stage biopharmaceutical company developing a technology platform for targeted therapeutic enhancement – Acoustic Cluster Therapy (ACT®). ACT® is a unique approach to ultrasound-mediated, targeted drug enhancement – with the potential to significantly amplify the clinical utility of a wide range of therapeutic agents across a multitude of indications including within oncology (chemotherapy, immunotherapy), infectious diseases, and neurological conditions.

Mitral Regurgitation is the third most common cardiovascular disease that occurs when there is backward flow of blood across the mitral valve. It is highly prevalent, debilitating for patients, and deadly if untreated. The market is expected to be larger than the TAVR market, currently a $6B market. The CardioMech device is an artificial chord that is designed to reduce or eliminate regurgitation and to restore the native anatomy. This catheter-based therapy is intended to be a simple and straightforward procedure and an alternative therapy option for both patients eligible for open-heart surgery and those considered surgically ineligible. Therefore, the CardioMech device can potentially reduce the need for open-heart surgery and may lessen the need for watchful waiting in younger and healthier patients. Caution: Investigational device. Limited by law to investigational use.

Curida is a Contract Development and Manufacturing Organization for Pharmaceuticals, based in Norway. We are building on more than 40 years of experience and offer premium quality manufacturing to international pharma companies. Curida has core competency on sterile and aseptic manufacturing of liquid pharmaceuticals. Our core technologies are blow-fill-seal (BFS) and nasal spray. We work with companies ranging from small biotech to Big Pharma. We have a lean and flexible organization that will, enabling a strong partnership with our customers.

SpinChip Diagnostics is a medical device company that is developing a game changing and proprietary platform for in vitro diagnostics point of care analyses. The platform will make it possible to perform a broader range of analyses using one platform and to transfer analyses from central laboratories to point of care without loss in quality. All analyses are performed within a few minutes based on a fraction of a droplet of blood and at a unit cost significantly lower than other point of care platforms.

Numascale is the eco-system enabler for scale-up in the computer industry. Numascale provides state of the art Node Controller IP, technology and components for Intel UPI and AMD Hypertransport. Numascale is also developing IP and products for CXL. www.numascale.com